SS
HOWL icon

SBI Securities’s Werewolf Therapeutics HOWL Stock Holding History

SBI Securities’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36 Buy
100
+20
+25% +$12 ﹤0.01% 3741
2026
Q1 		$67 Buy
80
+40
+100% +$27 ﹤0.01% 3514
2025
Q4 		$25 Sell
40
-1
-2% -$1 ﹤0.01% 3730
2025
Q3 		$81 Buy
41
+1
+3% +$1 ﹤0.01% 3579
2025
Q2 		$44 Hold
40
– – ﹤0.01% 3749
2025
Q1 		$39 Hold
40
– – ﹤0.01% 3708
2024
Q4 		$59 Buy
+40
New +$82 ﹤0.01% 3602

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SBI Securities's HOWL Position: Q2 2026 in Review

SBI Securities increased its Werewolf Therapeutics (HOWL) stake by 25% in Q2 2026, buying an estimated $12 and bringing the position to 100 shares worth $36. The position accounts for ﹤0.01% of the portfolio, ranked #3741.

SBI Securities first reported a position in HOWL in Q4 2024 and has held it in 7 quarters since. The position peaked at $81 in Q3 2025. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • SBI Securities held 100 shares of Werewolf Therapeutics worth $36 as of Q2 2026.
  • SBI Securities bought 20 Werewolf Therapeutics shares in Q2 2026, an estimated $12.
  • Werewolf Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3741 holding.
  • SBI Securities first reported a position in Werewolf Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Werewolf Therapeutics position peaked at $81 in Q3 2025.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.